Not a company that weathered the major selloff since January, therefore not a great company. Look for companies that wont get hurt if a recession comes. Avoid this company.

Yield oriented companies make a lot of sense in this market. You wouldn’t want to see this stock trade below $37. Set $35 as a stop. Fundamentally the companies in pretty good shape. Could reach $45 in the next year.

The stock’s been consolidating since April last year. This could do pretty well. Likes steady growers in this environment, which this is. In this type of environment, outsourcing companies tend to do pretty well.

Would be a buyer of this stock. It’s performing really well. Comfortable holding it here. Likely to raise its dividend.

The pharma sector has had a rotten time, declining earnings. This company will have worst earnings than last year. Would avoid the stock (Not value investors, don’t try to pick bottoms), in a declining environment this will perform poorly.

A great play on economic strength in western Canada. Not inexpensive, probably the most expensive in Canada. They’re had tremendous growth. You’re fighting the tide with the financials.

The company depends on being able to raise funding to buy assets. Over the last 9 months, the price people are willing to pay for assets has come down and the funding costs have increased. They are seeing a squeeze. Less attractive. Not the right stock for this type of environment.